Global Whole Exome Sequencing Market 2023
According to the latest estimates, the global whole exome sequencing market is predicted to be growing at a CAGR of over 14.2% from 2023 to 2029. The top market companies…
$2,950.00
The GvHD treatment market was valued at USD 678.1 million in 2022 and is projected to reach USD 1,039 million by 2029, with a CAGR of 6.0%. GvHD occurs when the donor’s T-cells attack the recipient’s healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.
The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global GvHD treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
The market is segmented based on various factors, including drug class, treatment type, gender, and geography.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, others
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males
Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% to 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.
Key players in the GvHD treatment market include AltruBio, Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd., Elsalys Biotech SAS, Equillium, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V., among others.
To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, geography.
To identify drivers and challenges for the global GvHD treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.
Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY DRUG CLASS
5.1 Calcineurin inhibitors
5.2 Corticosteroids
5.3 Kinase inhibitors
5.4 TNF-alpha inhibitors
5.5 Others
PART 6. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY TREATMENT TYPE
6.1 Acute GVHD
6.2 Chronic GVHD
6.3 GVHD prophylaxis
PART 7. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GENDER
7.1 Females
7.2 Males
PART 8. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 APAC
PART 9. COMPANY PROFILES
9.1 AltruBio, Inc.
9.2 ASC Therapeutics Inc.
9.3 Bristol-Myers Squibb Company
9.4 Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
9.5 Elsalys Biotech SAS
9.6 Equillium, Inc.
9.7 F. Hoffmann-La Roche AG
9.8 Genentech, Inc.
9.9 GSK plc
9.10 Incyte Corporation
9.11 Janssen Global Services, LLC
9.12 Jazz Pharmaceuticals plc
9.13 JCR Pharmaceuticals Co., Ltd.
9.14 Kadmon Corporation (Sanofi S.A.)
9.15 MaaT Pharma SA
9.16 Mallinckrodt PLC
9.17 medac GmbH
9.18 Merck Corporation
9.19 Mesoblast Limited
9.20 MiNK Therapeutics, Inc.
9.21 Neovii Pharmaceuticals AG
9.22 Novartis AG
9.23 Pharmacyclics LLC
9.24 Pluri Inc.
9.25 REGiMMUNE Corporation
9.26 Sun Pharmaceutical Industries Ltd.
9.27 Syndax Pharmaceuticals, Inc.
9.28 Takeda Pharmaceutical Company Limited
9.29 Xenikos B.V.
DISCLAIMER
AltruBio, Inc.
ASC Therapeutics Inc.
Bristol-Myers Squibb Company
Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
Elsalys Biotech SAS
Equillium, Inc.
F. Hoffmann-La Roche AG
Genentech, Inc.
GSK plc
Incyte Corporation
Janssen Global Services, LLC
Jazz Pharmaceuticals plc
JCR Pharmaceuticals Co., Ltd.
Kadmon Corporation (Sanofi S.A.)
MaaT Pharma SA
Mallinckrodt PLC
medac GmbH
Merck Corporation
Mesoblast Limited
MiNK Therapeutics, Inc.
Neovii Pharmaceuticals AG
Novartis AG
Pharmacyclics LLC
Pluri Inc.
REGiMMUNE Corporation
Sun Pharmaceutical Industries Ltd.
Syndax Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Xenikos B.V.
REPORT ATTRIBUTE | DETAILS |
---|---|
Market Size (2022) | USD 678.1 Million |
Base Year | 2022 |
Forecast Year | 2023-2029 |
CAGR (2023-2029) | 6.04% |
Pages | 93 |
Segments By | Drug Class, Treatment Type, Gender, Geography |
Regions Covered | Global |
Key Players | AltruBio Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co. Ltd., Elsalys Biotech SAS, Equillium Inc., F. Hoffmann-La Roche AG, Genentech Inc., GSK plc, Incyte Corporation, Janssen Global Services LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co. Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V. |
According to the latest estimates, the global whole exome sequencing market is predicted to be growing at a CAGR of over 14.2% from 2023 to 2029. The top market companies…
The global continuous bioprocessing market, in terms of revenue, is expected to grow by 17.9 percent annually through 2029, according to the latest estimates. The top market companies profiles included…
The global virology testing market is projected to expand at a CAGR of ~1.2 percent across the forecast period of 2023 – 2029, according to the latest edition of the…
Please fill out our form and we will get back to you.